Human Services (HHS), announces a webinar entitled, "CDC STI Treatment Guidelines Update". The purpose of the webinar is for CDC to receive comments from potential users on the proposed updated guidelines. This webinar is an opportunity for all interested parties to ask questions and provide feedback, but is specifically directed toward clinicians, such as medical doctors, nurse practitioners, and physician's assistants. CDC will consider comments made during the webinar prior to finalizing the updated STI Treatment Guidelines for publication.

**DATES:** The webinar will be held on December 18, 2020 from 2 p.m. to 4 p.m. EST. Registration instructions can be found on the website, https://www.cdc.gov/std/treatment/default.htm.

ADDRESSES: The webinar will be broadcast from the Centers for Disease Control and Prevention, 1600 Clifton Road NE, Atlanta, Georgia 30329.

#### FOR FURTHER INFORMATION CONTACT:

Quinn Haaga, Public Health Advisor, CDC, 1600 Clifton Road NE, MS–US 12– 2, Atlanta, GA 30329, stdtxguidelines@ cdc.gov.

SUPPLEMENTARY INFORMATION: The CDC's STI Treatment Guidelines Webinar is a public presentation of proposed updates to the CDC's 2015 STD Treatment Guidelines. The webinar will include discussions of proposed changes to CDC's 2015 STD Treatment Guidelines focusing on (1) changes to testing, management, and/or treatment recommendations for Neisseria gonorrhoeae, Chlamydia trachomatis, Trichomonas vaginalis treatment; (2) role of metronidazole in pelvic inflammatory disease treatment; (3) alternative treatment options for bacterial vaginosis; (4) management of Mycoplasma genitalium; and (5) two step testing for serologic diagnosis of genital HSV2. Physicians and other health-care providers can use these guidelines to assist in the prevention and treatment of STIs. Comments and questions on the proposed changes may be made during the webinar only.

Please refer to the posted agenda for updates about the webinar one week prior to the meeting. Information will be provided on the following website when it becomes available. https://www.cdc.gov/std/treatment/default.htm. A recording of the webinar and accompanying transcripts will be available by January 17, 2021 on the website listed above. In addition, CDC's responses to questions from the webinar will also be available February 15, 2021 on this website.

Participants must register by December 17, 2020. This is a webinar-

only event and there will be no on-site participation at the CDC broadcast facility.

#### Sandra Cashman,

Executive Secretary, Centers for Disease Control and Prevention.

[FR Doc. 2020–26974 Filed 12–8–20; 8:45 am]

BILLING CODE 4163-18-P

### DEPARTMENT OF HEALTH AND HUMAN SERVICES

## Centers for Disease Control and Prevention

[Docket No. CDC-2020-0122]

## Advisory Committee on Immunization Practices (ACIP)

**AGENCY:** Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS).

**ACTION:** Notice of meeting and request for comment.

**SUMMARY:** In accordance with the Federal Advisory Committee Act, the Centers for Disease Control and Prevention (CDC), announces the following meeting of the Advisory Committee on Immunization Practices (ACIP). This meeting is open to the public. The meeting will be webcast live via the World Wide Web.

**DATES:** The meeting will be held on December 11, 2020 from 12:00 p.m. to 5:00 p.m. EST and December 13, 2020 from 12:00 p.m. to 4:00 p.m. EST (times subject to change, see the ACIP website for any updates: http://www.cdc.gov/vaccines/acip/index.html).

Written comments must be received on or before December 14, 2020.

**ADDRESSES:** For more information on ACIP please visit the ACIP website: http://www.cdc.gov/vaccines/acip/index.html.

You may submit comments, identified by Docket No. CDC–2020–0122 by any of the following methods:

- Federal eRulemaking Portal: https://www.regulations.gov. Follow the instructions for submitting comments.
- Mail: Docket No. CDC-2020-0122, c/o Attn: December 11 and 13, 2020 ACIP Meeting, Centers for Disease Control and Prevention, 1600 Clifton Road NE, MS H24-8, Atlanta, GA 30329-4027.

Instructions: All submissions received must include the Agency name and Docket Number. All relevant comments received in conformance with the <a href="https://www.regulations.gov">https://www.regulations.gov</a> suitability policy will be posted without change to <a href="https://www.regulations.gov">https://www.regulations.gov</a>, including any personal information provided. For

access to the docket to read background documents or comments received, go to https://www.regulations.gov.

#### FOR FURTHER INFORMATION CONTACT:

Stephanie Thomas, ACIP Committee Management Specialist, Centers for Disease Control and Prevention, National Center for Immunization and Respiratory Diseases, 1600 Clifton Road NE, MS–H24–8, Atlanta, GA 30329–4027; Telephone: 404–639–8367; Email: ACIP@cdc.gov.

SUPPLEMENTARY INFORMATION: In accordance with 41 CFR 102-3.150(b), less than 15 calendar days' notice is being given for this meeting due to the exceptional circumstances of the COVID-19 pandemic and rapidly evolving COVID-19 vaccine development and regulatory processes. The Secretary of Health and Human Services has determined that COVID-19 is a Public Health Emergency. A notice of this ACIP meeting has also been posted on CDC's ACIP website at: http:// www.cdc.gov/vaccines/acip/index.html. In addition, CDC has sent notice of this ACIP meeting by email to those who subscribe to receive email updates about ACIP.

Purpose: The committee is charged with advising the Director, CDC, on the use of immunizing agents. In addition, under 42 U.S.C. 1396s, the committee is mandated to establish and periodically review and, as appropriate, revise the list of vaccines for administration to vaccine-eligible children through the Vaccines for Children (VFC) program, along with schedules regarding dosing interval, dosage, and contraindications to administration of vaccines. Further, under provisions of the Affordable Care Act, section 2713 of the Public Health Service Act, immunization recommendations of the ACIP that have been approved by the Director of the Centers for Disease Control and Prevention and appear on CDC immunization schedules must be covered by applicable health plans.

Matters To Be Considered: The agenda will include discussions on COVID–19 vaccine. A recommendation vote(s) is scheduled. Agenda items are subject to change as priorities dictate. For more information on the meeting agenda visit https://www.cdc.gov/vaccines/acip/meetings/meetings-info.html.

Meeting Information: The meeting will be webcast live via the World Wide Web; for more information on ACIP please visit the ACIP website: http://www.cdc.gov/vaccines/acip/index.html.

#### **Public Participation**

Interested persons or organizations are invited to participate by submitting

written views, recommendations, and data. Please note that comments received, including attachments and other supporting materials are part of the public record and are subject to public disclosure. Do not include any information in your comment or supporting materials that you consider confidential or inappropriate for public disclosure. If you include your name, contact information, or other information that identifies you in the body of your comments, that information will be on public display. CDC will review all submissions and may choose to redact, or withhold, submissions containing private or proprietary information such as Social Security numbers, medical information, inappropriate language, or duplicate/ near duplicate examples of a mass-mail campaign. CDC will carefully consider all comments submitted into the docket. CDC does not accept comment by email.

Written Public Comment: Written comments must be received on or before December 14, 2020. Oral Public Comment: This meeting will include time for members of the public to make an oral comment. Oral public comment will occur before any scheduled votes including all votes relevant to the ACIP's Affordable Care Act and Vaccines for Children Program roles. Priority will be given to individuals who submit a request to make an oral public comment before the meeting according to the procedures below.

Procedure for Oral Public Comment: All persons interested in making an oral public comment at the December 13, 2020 ACIP meeting must submit a request at http://www.cdc.gov/vaccines/ acip/meetings/ no later than 11:59 p.m., EST, December 11, 2020 according to the instructions provided.

If the number of persons requesting to speak is greater than can be reasonably accommodated during the scheduled time, CDC will conduct a lottery to determine the speakers for the scheduled public comment session. CDC staff will notify individuals regarding their request to speak by email by 12:00 p.m., EST, December 12, 2020. To accommodate the significant interest in participation in the oral public comment session of ACIP meetings, each speaker will be limited to 3 minutes, and each speaker may only speak once per meeting.

The Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, Centers for Disease Control and Prevention, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

#### Kalwant Smagh,

Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, Centers for Disease Control and Prevention.

[FR Doc. 2020–27133 Filed 12–7–20; 4:15 pm]

BILLING CODE 4163-18-P

# DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Administration for Children and Families

[OMB No. 0970-0234]

Proposed Information Collection Activity; Social Services Block Grant (SSBG) Post-Expenditure Report, Pre-Expenditure Report, and Intended Use Plan

**AGENCY:** Office of Community Services, Administration for Children and Families, HHS.

**ACTION:** Request for Public Comment.

SUMMARY: The Administration for Children and Families (ACF) is requesting a revision to the Social Services Block Grant (SSBG) Post-Expenditure Report, Pre-Expenditure Report, and Intended Use Plan (OMB #0970–0234), previously titled, "Social Services Block Grant (SSBG) Post-Expenditure Report"). ACF is proposing to expand the information collection to include the collection of states' Intended Use Plans and retitle the information collection to clarify the role of the Pre-Expenditure Report.

**DATES:** Comments due within 60 days of publication. In compliance with the requirements of Section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995, ACF is soliciting public comment on the specific aspects of the information collection described above.

**ADDRESSES:** Copies of the proposed collection of information can be obtained and comments may be forwarded by emailing *infocollection@acf.hhs.gov*. Alternatively, copies can also be obtained by writing to the

Administration for Children and Families, Office of Planning, Research, and Evaluation (OPRE), 330 C Street SW, Washington, DC 20201, Attn: ACF Reports Clearance Officer. All requests, emailed or written, should be identified by the title of the information collection.

#### SUPPLEMENTARY INFORMATION:

Description: On an annual basis, states and territories are required to submit the following reports: (1) An Intended Use Plan that provides data and narrative descriptions related to the state's SSBG program. The Intended Use Plan includes details about the delivery of SSBG services and the state agency administering the SSBG Program. ACF is proposing to expand the currently approved information collection to include collection of states' Intended Use Plans. Grantees are required to submit their Intended Use Plans no less than 30 days prior to the start of the budget period covered by the report. (2) A Pre-Expenditure Report that demonstrates the state's anticipated allocation of SSBG funding among the 29 pre-defined SSBG service categories. Historically, states have submitted this report using the Post-Expenditure Report Form, and the associated burden is included in the currently approved information collection. Grantees are required to submit their Pre-Expenditure Report no less than 30 days prior to the start of the budget period covered by the report. (3) A Post-Expenditure Report that details the state's actual use of SSBG funding among each of the 29 service categories. Grantees are required to submit their Post-Expenditure Report within 6 months of the end of the period covered by the report.

Respondents: Agencies that administer the SSBG at the state or territory level, including the 50 states; District of Columbia; Puerto Rico; and the territories of American Samoa, Guam, the Virgin Islands, and the Commonwealth of Northern Mariana Islands.

### **Annual Burden Estimates**

This request is specific to the Intended Use Plan. Currently approved materials and associated burden can be found at: https://www.reginfo.gov/public/do/PRAViewICR?ref\_nbr=202011-0970-006.

Instrument	Annual number of respondents	Annual number of responses per respondent	Average burden hours per response	Total/annual burden hours
Intended Use Plan	56	1	40	2,240